ClinicaliQ Trial Snapshot
- A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome — Recruiting • Phase III • NCT04462770.
- Clemizole added to standard treatment reduced seizures more than placebo in Dravet syndrome patients.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole hydrochloride (EPX-100) as adjunctive therapy in children and adult participants with Dravet syndrome (DS). Conditions: Dravet Syndrome Interventions: Clemizole HCl, Placebo Lead Sponsor: Epygenix Planned Enrollment: 150 participants